Skip to main content

Table 3 Overall survival according to PDGFRα and PDGFRβ mutational status

From: PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome

Mutational status

Patients N (%)

Overall survival

  

Median (months)

% at 5y

HR

P

PDGFR-A13

     

  · WT (AA)

60 (82%)

37.1

14%

0.96

0.934

  · SNP (AG)

13 (18%)

21.7

41%

  

PDGFR-B19

     

  · WT (AA)

33 (42%)

NR

51%

1.93

0.073

  · SNP (AG,GG)

45 (58%)

37.1

17%

  
  1. WT: wild type; SNP: single nucleotide polymorphism; N: number; 5y: 5 years; HR: hazard ratio; NR: not reached.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us